摘要
本研究测定了５６例ＨＣＨ 患者发病４８小时内血中凝血功能、抗凝及纤溶状态的９项相关指标。结果表明，ＨＣＨ患者无凝血功能障碍，抗凝血酶消耗性降低，纤溶活性代偿性轻度升高。据此认为抗纤溶药不宜用于治疗ＨＣＨ。
Nine varibles of blood coagulation,anticoagulation and fibrinolysis in 56 patients with HCH were assayed. Results showed that in the initial stage of HCH blood coagulation was not affected. antithrombin Ⅲ consumption decreased, fibrinolytic activity compensationally enhanced, while coagulation-fibrinolysis balance kept well. These data suggest that antifibrinolytic drugs would not be necessary for treatment in patients with HCH.
出处
《临床神经病学杂志》
CAS
1994年第1期17-19,共3页
Journal of Clinical Neurology
